Markets & Investing
Greg Mayes, CEO of Reunion, Sits in the Investor Hotseat on January 16th
During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Greg Mayes of Reunion Neuroscience. Greg currently leads…
During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Greg Mayes of Reunion Neuroscience.
Greg currently leads Reunion Neuroscience ($REUN) as President and CEO and Board Member (2022 to present). As Reunion’s President and CEO, Mr. Mayes’ initial focus is on the successful completion of the Company’s Phase 1 clinical trial with its lead asset, RE104, a novel serotonergic psychedelic, which commenced in August 2022, and the planned launch of its Phase 2 study in postpartum depression, which is expected to commence in 2023. Mr. Mayes will also drive and accelerate Reunion’s preclinical RE200 research, which is focused on the discovery of selective and specific serotonergic psychedelics.
How will Greg handle the hot seat? Tune in to find out.
As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.
If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can return to the Hotseat livestream page at the time of the event.
To RSVP to ensure your spot, please fill out the form below.
A Transcription Will Be Available Following the Event
-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Ketamine1 week ago
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
-
Psychedelics1 week ago
Optimi Health Provides Corporate Update
-
Law & Regulation1 week ago
Horizons talk shifts from investors to insurance
-
Law & Regulation1 week ago
DEA psychedelics ban hearing halted by lawsuit
-
Law & Regulation6 days ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics4 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001